The constellation of hypertensive heart disease

Hellenic Journal of Cardiology

Volumn 49, Issue 2, 2008, Pages 92-99

  Pavlopoulos, Harry ^a   Nihoyannopoulos, Petros ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Diastole; Heart failure; Hypertension

Indexed keywords

LOSARTAN;

APOPTOSIS; ARTERIAL STIFFNESS; CORONARY ARTERY BLOOD FLOW; DIASTOLIC DYSFUNCTION; ENDOTHELIAL DYSFUNCTION; HEART ARRHYTHMIA; HEART FAILURE; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; INFLAMMATION; NONHUMAN; REVIEW;

HEART DISEASES; HUMANS; HYPERTENSION;

EID: 43049090888     PISSN: 10117970     EISSN: 10117970     Source Type: Journal    
DOI: None     Document Type: Review

References (104)

1. Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ; Comparative Risk Assessment Collaborating Group: Selected major risk factors and global and regional burden of disease. Lancet 2002; 360: 1347-1360.
2. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK: The progression from hypertension to congestive heart failure. JAMA 1996; 275: 1557-1562.
3. Querejeta R, Varo N, Lopez B, et al: Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation 2000; 14: 1729-1735.
4. Weber KT: Targeting pathologic remodeling: concepts of cardioprotection and reparation. Circulation 2000; 102: 1342-1345.
5. Brilla CG, Janicki JS, Weber KT: Impaired diastolic function and coronary reserve in genetic hypertension: role of interstitial fibrosis and medial thickening of intramyocardial coronary arteries. Circ Res 1991; 69: 107-115.
6. Schwartzkopff B, Brehm M, Mundhenke M, Strauer BE: Repair of coronary arterioles after treatment with perindopril in hypertensive heart disease. Hypertension. 2000; 36: 220-225.
7. Brilla CG, Funck RC, Rupp H: Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 2000; 102: 1388-1393.
8. Rossi MA: Pathologic fibrosis and connective tissue matrix in left ventricular hypertrophy due to chronic arterial hypertension in humans. J Hypertens 1998; 16: 1031-1041.
9. Baker KM, Booz GW, Dostal DE: Cardiac actions of angiotensin II: role of an intracardiac renin-angiotensin system. Annu Rev Physiol 1992; 54: 227-241.
10. Booz GW, Baker KM: Molecular signalling mechanisms controlling growth and function of cardiac fibroblasts. Cardiovasc Res 1995; 30: 537-543.
11. Lamb HJ, Beyerbacht HP, van der Laarse A, et al: Diastolic dysfunction in hypertensive heart disease is associated with altered myocardial metabolism. Circulation 1999; 99: 2261-2267.
12. Hunter WC: Role of myofilaments and calcium handling in left ventricular relaxation. Cardiol Clin 2000; 18: 443-457.
13. Ichihara S, Senbonmatsu T, Price E Jr, Ichiki T, Gaffney FA, Inagami T: Angiotensin II type 2 receptor is essential for left ventricular hypertrophy and cardiac fibrosis in chronic angiotensin II-induced hypertension. Circulation 2001; 104: 346-351.
14. Shan K, Bick RJ, Poindexter BJ, et al: Relation of tissue Doppler derived myocardial velocities to myocardial structure and beta-adrenergic receptor density in humans. J Am Coll Cardiol 2000; 36: 891-896.
15. Schafer S, Kelm M, Mingers S, Strauer BE: Left ventricular remodeling impairs coronary flow reserve in hypertensive patients. J Hypertens 2002; 20: 1431-1437.
16. Youn HJ, Ihm SH, Lee JM, et al: Relation between flow reserve capacity of penetrating intramyocardial coronary arteries and myocardial fibrosis in hypertension: study using transthoracic Doppler echocardiography. J Am Soc Echocardiogr 2006; 19: 373-378.
17. Treasure CB, Klein JL, Vita JA, et al: Hypertension and left ventricular hypertrophy are associated with impaired endothelium-mediated relaxation in human coronary resistance vessels. Circulation 1993; 87: 86-93.
18. Anderson HV, Stokes MJ, Leon M, et al: Coronary artery flow velocity is related to lumen area and regional left ventricular mass. Circulation 2000; 102: 48-54.
19. Hittinger L, Mirsky I, Shen YT, Patrick TA, Bishop SP, Vatner SF: Hemodynamic mechanisms responsible for reduced subendocardial coronary reserve in dogs with severe left ventricular hypertrophy. Circulation 1995; 92: 978-986.
20. Hittinger L, Shen YT, Patrick TA, et al: Mechanisms of subendocardial dysfunction in response to exercise in dogs with severe left ventricular hypertrophy. Circ Res 1992; 71: 423-434.
21. Tadaoka S, Wada Y, Kimura A, et al: Effect of left ventricular hypertrophy secondary to systemic hypertension on left coronary artery flow dynamics. Cardiovasc Res 1991; 25: 955-964.
22. Michel JB, Salzmann JL, Ossondo Nlom M, Bruneval P, Barres D, Camilleri JP: Morphometric analysis of collagen network and plasma perfused capillary bed in the myocardium of rats during evolution of cardiac hypertrophy. Basic Res Cardiol 1986; 2: 142-154.
23. Galderisi M, Petrocelli A, Alfieri A, Garofalo M, de Divitiis O: Impact of ambulatory blood pressure on left ventricular diastolic dysfunction arterial systemic hypertension. Am J Cardiol 1996; 77: 579-601.
24. Inouye I, Massie B, Loge D, et al: Abnormal left ventricular filling: an early finding in mild to moderate systemic hypertension. Am J Cardiol 1984; 53: 120-126.
25. Laine H, Raitakari OT, Niinikoski H, et al: Early impairment of coronary flow reserve in young men with borderline hypertension J Am Coll Cardiol 1998; 1: 147-153.
26. Schwartzkopff B, Motz W, Frenzel H, Vogt M, Knauer S, Strauer BE: Structural and functional alterations of the intramyocardial coronary arterioles in patients with arterial hypertension. Circulation 1993; 88: 993-1003.
27. Vogt M, Motz W, Strauer BE: Coronary hemodynamics in hypertensive heart disease. Eur Heart J 1992; 13: 44-49.
28. Treasure CB, Klein JL, Vita JA, et al: Hypertension and left ventricular hypertrophy are associated with impaired endothelium-mediated relaxation in human coronary resistance vessels. Circulation 1993; 87: 86-93.
29. Zeiher AM, Drexler H, Wollschläger H, Just H: Modulation of coronary vasomotor tone: progressive endothelial dysfunction with different early stages of coronary atherosclerosis. Circulation 1991; 83: 391-401.
30. Chilian WM, Eastham CL, Marcus ML: Microvascular distribution of coronary vascular resistance in beating left ventricle. Am J Physiol 1986; 251: 779-786.
31. Zeiher AM, Krause T, Schächinger V, Minners J, Moser E: Impaired endothelium-dependent vasodilation of coronary resistance vessels is associated with exercise-induced myocardial ischemia. Circulation 1995; 91: 2345-2352.
32. Galderisi M, Cicala S, Caso P, de Divitiis O: Coronary flow reserve and myocardial diastolic dysfunction in arterial hypertension. Am J Cardiol 2002; 90: 860-864.
33. Komuro I, Katoh Y, Kaida T, et al: Mechanical loading stimulates cell hypertrophy and specific gene expression in cultured rat cardiac myocytes. J Biol Chem 1991; 266: 1265-1268.
34. Leite-Moreira AF, Gillebert TC: The physiology of left ventricular pressure fall. Rev Port Cardiol 2000; 19: 1015-1021.
35. Leite-Moreira AF, Correia-Pinto J: Load as an acute determinant of end-diastolic pressure-volume relation. Am J Physiol Heart Circ Physiol 2001; 280: 51-59.
36. Gillebert TC, Leite-Moreira AF, De Hert SG: Load dependent diastolic dysfunction in heart failure. Heart Fail Rev 2000; 5: 345-355.
37. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP: Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561-1566.
38. Grossman W, Jones D, McLaurin LP: Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest 1975; 56: 56-64.
39. Sadoshima J, Izumo S: The cellular and molecular response of cardiac myocytes to mechanical stress. Annu Rev Physiol 1997; 59: 551-571.
40. Zou Y, Akazawa H, Qin Y, et al: Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. Nat Cell Biol 2004; 6: 499-506.
41. Unger T: The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol 2002; 89: 3-10.
42. Seccia TM, Belloni AS, Kreutz R, et al: Cardiac fibrosis occurs early and involves endothelin and AT-1 receptors in hypertension due to endogenous angiotensin II. J Am Coll Cardiol 2003; 41: 666-673.
43. Laurent S, Boutouyrie P, Asmar R, et al: Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001; 37: 1236-1241.
44. Zieman SJ, Melenovsky V, Kass DA: Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol 2005; 25: 932-943.
45. Schwartz SM, Heimark RL, Majesty MW: Developmental mechanisms underlying pathology of arteries. Physiol Rev 1990; 70: 1177-1198.
46. Xu C, Zarins CK, Pannaraj PS, Bassiouny HS, Glagov S: Hypercholesterolemia superimposed by experimental hypertension induces differential distribution of collagen and elastin. Arterioscler Thromb Vasc Biol 2000; 20: 2566-2572.
47. Heerkens EHJ, Izzard AS, Heagerty AM: Integrins, vascular remodeling and hypertension. Hypertension 2007; 49: 1-4.
48. Mahmud A, Feely J: Arterial stiffness is related to systemic inflammation in essential hypertension. Hypertension 2005; 46: 1118-1122.
49. Dzau VJ: Significance of the vascular renin-angiotensin pathway. Hypertension 1986; 8: 553-559.
50. Yanagisawa M, Kurihara H, Kimura S, et al: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411-415.
51. Gurtner GH, Burke-Wolin T: Interactions of oxidant stress and vascular reactivity. Am J Physiol 1991; 260: 207-211.
52. Lacolley P, Labat C, Pujol A, Delcayre C, Benetos A, Safar M: Increased carotid wall elastic modulus and fibronectin in aldosterone salt-treated rats: effects of eplerenone. Circulation 2002; 106: 2848-2853.
53. Park JB, Schiffrin EL: ET(A) receptor antagonist prevents blood pressure elevation and vascular remodeling in aldosterone-infused rats. Hypertension 2001; 37: 1444-1449.
54. O'Rourke MF: Diastolic heart failure, diastolic left ventricular dysfunction and exercise intolerance. J Am Coll Cardiol 2001; 38: 803-805.
55. Mottram PM, Haluska BA, Leano R, Carlier S, Case C, Marwick TH: Relation of arterial stiffness to diastolic dysfunction in hypertensive heart disease. Heart 2005; 91: 1551-1556.
56. Kawaguchi M, Hay I, Fetics B, Kass DA: Combined ventricular systolic, arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations. Circulation 2003; 107: 714-720.
57. Mancia G, De Backer G, Dominiczak A, et al; The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC): 2007 Guidelines for the management of arterial hypertension. Eur Heart J 2007; 28: 1462-1536.
58. Panza JA, Quyyumi AA, Brush JE Jr, Epstein SE: Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990; 323: 22-27.
59. Park JB, Charbonneau F, Schiffrin EL: Correlation of endothelial function in large and small arteries in human essential hypertension. J Hypertens 2001; 19: 415-420.
60. Schiffrin EL, Park JB, Intengan HD, Touyz RM: Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation 2000; 101: 1653-1659.
61. Park JB, Schiffrin EL: Small artery remodeling is the most prevalent (earliest?) form of target organ damage in mild essential hypertension. J Hypertens 2001; 19: 921-930.
62. Endemann DH, Schiffrin EL: Endothelial dysfunction. J Am Soc Nephrol. 2004; 15: 1983-1992.
63. Hermann M, Flammer A, Lüscher TF: Nitric oxide in hypertension. J Clin Hypertens 2006; 8: 17-29.
64. Cai H, Harrison DG: Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000; 87: 840-844.
65. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T: Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001; 104: 2673-2678.
66. Panza JA, Garc?a CE, Kilcoyne CM: Impaired endothelium-dependent vasodilation in patients with essential hypertension: evidence that nitric oxide abnormality is not localized to a single signal transduction pathway. Circulation. 1995; 91: 1732-1738.
67. Higashi Y, Sasaki S, Nakagawa K: Tetrahydrobiopterin enhances forearm vascular response to acetylcholine in both normotensive and hypertensive individuals. Am J Hypertens 2002; 15: 326-332.
68. Achan V, Broadhead M, Malaki M: Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 2003; 23: 1455-1459.
69. Rajagopalan S, Kurz S, Munzel T, et al: Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 1996; 7: 1916-1923.
70. Schiffrin EL, Park JB, Intengan HD, Touyz RM: Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation 2000; 101: 1653-1659.
71. Blake GJ, Rifai N, Buring JE: Blood pressure, C-reactive protein, and risk of future cardiovascular events. Circulation 2003; 108: 2993-2999.
72. Chappell DC, Varner SE, Nerem RM, Medford RM, Alexander RW: Oscillatory shear stress stimulates adhesion molecule expression in cultured human endothelium. Circ Res 1998; 82: 532-539.
73. Wung BS, Cheng JJ, Chao YJ, Lin J, Shyy YJ, Wang DL: Cyclical strain increases monocyte chemotactic protein-1 secretion in human endothelial cells. Am J Physiol 1996; 270: 1462-1468.
74. Rocha R, Rudolph AE, Frierdich GE, et al: Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol 2002; 283: 1802-1810.
75. Rocha R, Martin-Berger CL, Yang P, Scherrer R, Delyani J, McMahon E: Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology 2002; 143: 4828-4836.
76. Verma S, Wang C-H, Li S-H, et al: A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002; 106: 913-919.
77. Verma S, Li S-H, Badiwala MV, et al: Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 2002; 105: 1890-1896.
78. Ikeda S, Hamada M, Qu P, Hiasa G, Hashida H, Shigematsu Y: Relationship between cardiomyocyte cell death and cardiac function during hypertensive cardiac remodeling in Dahl rats. Clin Sci (Lond) 2002; 102: 329-335.
79. D?ez J, Panizo A, Herna'ndez M, et al: Cardiomyocyte apoptosis and cardiac angiotensin-converting enzyme in spontaneously hypertensive rats. Hypertension 1997; 30: 1029-1034.
80. Gonzalez A, Lopez B, Ravassa S, et al: Stimulation of cardiac apoptosis in essential hypertension: potential role of angiotensin II. Hypertension 2002; 39: 75-80.
81. Li Z, Bing OH, Long X, Robinson KG, Lakatta EG: Increased cardiomyocyte apoptosis during the transition to heart failure in the spontaneously hypertensive rat. Am J Physiol Heart Circ Physiol 1997; 272: 2313-2319.
82. Gonzalez A, Fortuno MA, Querejeta R, et al: Cardiomyocyte apoptosis in hypertensive cardiomyopathy. Cardiovasc Res 2003; 59: 549-562.
83. Diep QN, El Mabrouk M, Yue P, Schiffrin EL: Effect of AT1 receptor blockade on cardiac apoptosis in angiotensin II-induced hypertension. Am J Physiol Heart Circ Physiol 2002; 282: 1635-1641.
84. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP: Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561-1566.
85. Frohlich ED, Apstein C, Chobanian AV, et al: The heart in hypertension. N Engl J Med 1992; 327: 998-1008.
86. Gaasch WH, Zile MR, Hoshino PK, Apstein CS, Blaustein AS: Stress-shortening relations and myocardial blood-flow in compensated and failing canine hearts with pressure-overload hypertrophy. Circulation 1989; 79: 872-883.
87. Nakao K, Minobe W, Roden R, Bristow MR, Leinwand LA: Myosin heavy chain gene expression in human heart failure. J Clin Invest 1997; 100: 2362-2370.
88. Weber KT: Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation. Circulation 1997; 96: 4065-4082.
89. Rockman HA, Koch WJ, Lefkowitz RJ: Seven trans-membrane spanning receptors and heart function. Nature 2002; 415: 206-212.
90. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM: Trends in prevalance and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006; 355: 251-259.
91. Paulus WJ, Tschöpe C, Sanderson JE, et al: How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007; 28: 2539-2550.
92. Bhatia RS, Tu JV, Lee DS, et al: Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006; 355: 260-269.
93. Hennersdorf MG, Strauer BE: Arterial hypertension and cardiac arrhythmias. J Hypertens 2001; 2: 167-177.
94. Kannel WB, Wolf PA, Benjamin EJ, Levy D: Prevalence, incidence, prognosis and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998; 82: 2-9.
95. Ciaroni S, Cuenoud L, Bloch A: Clinical study to investigate the predictive parameters for the onset of atrial fibrillation in patients with essential hypertension. Am Heart J 2000; 139: 814-819.
96. Tsang TSM, Gersh BJ, Appleton CP, et al: Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. J Am Coll Cardiol 2002; 40: 1636-1644.
97. McLenachan JM, Henderson E, Morris KI, Dargie HJ: Ventricular arrhythmias in patients with hypertensive left ventricular hypertrophy. N Engl J Med 1987; 317: 787-792.
98. Ghali JK, Kadakia S, Cooper RS, Liano YL: Impact of left ventricular hypertrophy on ventricular arrhythmias in the absence of coronary artery disease. J Am Coll Cardiol 1991; 17: 1277-1282.
99. Kannel WB, Schatzkin A: Sudden death: Lessons from subsets in population studies. J Am Coll Cardiol 1985; 5: 141-149.
100. Messerli FH: Hypertension and sudden cardiac death. Am J Hypertens 1999; 12: 181S-188S.
101. Konstantopoulou AS, Papargyriou IK, Antoniadou ES, Konstantopoulou PS, Papadogiannis DE: Masked hypertension: a new entity under investigation. Hellenic J Cardiol 2006; 4: 232-235.
102. Karagiannis A, Athyros VG, Papageorgiou A, Tziomalos K, Elisaf M: Should atenolol still be recommended as first-line therapy for primary hypertension? Hellenic J Cardiol 2006; 5: 298-307.
103. Laurent S, Cockcroft J, Van Bortel L, et al; European Network for Non-invasive Investigation of Large Arteries: Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006; 21: 2588-2605.
104. Ganotakis ES, Mikhailidis DP, Vardas PE: Atrial fibrillation, inflammation and statins. Hellenic J Cardiol 2006; 2: 51-53.